-
Violence-ridden Haiti in limbo as transitional council wraps up
-
Hundreds protest in Milan ahead of Winter Olympics
-
Suspect in murder of Colombian footballer Escobar killed in Mexico
-
Colombia's Rodriguez signs with MLS Minnesota United
-
Wainwright says England game still 'huge occasion' despite Welsh woes
-
WADA shrugs off USA withholding dues
-
France detects Russia-linked Epstein smear attempt against Macron
-
Winter Olympics to open with star-studded ceremony
-
Trump posts, then deletes, racist clip of Obamas as monkeys
-
Danone expands recall of infant formula batches in Europe
-
Trump deletes racist video post of Obamas as monkeys
-
Colombia's Rodriguez signs with MLS side Minnesota United
-
UK police probing Mandelson after Epstein revelations search properties
-
Russian drone hits Ukrainian animal shelter
-
US says new nuclear deal should include China, accuses Beijing of secret tests
-
French cycling hope Seixas dreaming of Tour de France debut
-
France detects Russia-linked Epstein smear attempt against Macron: govt source
-
EU nations back chemical recycling for plastic bottles
-
Terror at Friday prayers: witnesses describe blast rocking Islamabad mosque
-
Iran expects more US talks after 'positive atmosphere' in Oman
-
US says 'key participant' in 2012 attack on Benghazi mission arrested
-
Why bitcoin is losing its luster after stratospheric rise
-
Arteta apologises to Rosenior after disrespect row
-
Terror at Friday prayers: witness describes 'extremely powerful' blast in Islamabad
-
Winter Olympics men's downhill: Three things to watch
-
Ice dancers Chock and Bates shine as US lead Japan in team event
-
Stellantis takes massive hit on 'overestimation' of EV demand
-
Stocks rebound though tech stocks still suffer
-
Spanish PM urges caution as fresh rain heads for flood zone
-
Iran says to hold more talks with US despite Trump military threats
-
Russia accuses Kyiv of gun attack on army general in Moscow
-
Cambodia reveals damage to UNESCO-listed temple after Thailand clashes
-
Norway crown princess 'deeply regrets' Epstein friendship
-
Italy set for Winter Olympics opening ceremony as Vonn passes test
-
England's Jacks says players back under-fire skipper Brook '100 percent'
-
Carrick relishing Frank reunion as Man Utd host Spurs
-
Farrell keeps the faith in Irish still being at rugby's top table
-
Meloni, Vance hail 'shared values' amid pre-Olympic protests
-
Olympic freestyle champion Gremaud says passion for skiing carried her through dark times
-
US urges new three-way nuclear deal with Russia and China
-
Indonesia landslide death toll rises to 74
-
Hemetsberger a 'happy psychopath' after final downhill training
-
Suicide blast at Islamabad mosque kills at least 31, wounds over 130
-
Elton John accuses UK tabloids publisher of 'abhorrent' privacy breaches
-
Lindsey Vonn completes first downhill training run at Winter Olympics
-
Digital euro delay could leave Europe vulnerable, ECB warns
-
Feyi-Waboso out of England's Six Nations opener against Wales
-
Newcastle manager Howe pleads for Woltemade patience
-
German exports to US plunge as tariffs exact heavy cost
-
Portugal heads for presidential vote, fretting over storms and far-right
| CMSC | 0.02% | 23.555 | $ | |
| BCC | 2.77% | 91.7 | $ | |
| SCS | 0.12% | 16.14 | $ | |
| NGG | 1.26% | 87.995 | $ | |
| BCE | -1.55% | 25.18 | $ | |
| RIO | 2.61% | 93.565 | $ | |
| CMSD | 0.17% | 23.93 | $ | |
| JRI | 0.54% | 12.95 | $ | |
| AZN | 3.45% | 193.855 | $ | |
| BTI | 1.33% | 62.795 | $ | |
| GSK | 1.94% | 60.34 | $ | |
| RYCEF | 1.54% | 16.88 | $ | |
| RBGPF | 0.12% | 82.5 | $ | |
| VOD | 3.21% | 15.105 | $ | |
| RELX | -2.49% | 29.36 | $ | |
| BP | 2.09% | 38.985 | $ |
Biorasi Unveils New Website to Drive Sponsor Success with Biotech-Centric Strategies and Modular CRO Solutions
Relaunch puts customized CRO services front and center for today's Biotech and Biopharma innovators.
AVENTURA, FL / ACCESS Newswire / October 8, 2025 / Biorasi, a leading global full-service contract research organization (CRO), has relaunched its website to reflect a bold new direction: Empowering biotech sponsors with modular clinical trial solutions, AI-powered tools, and a renewed focus on sponsor-centric strategy.
"The future of clinical research belongs to those who can adapt, innovate, and deliver," said Chris O'Brien, CEO of Biorasi. "Our new website reflects a strategic evolution - one that puts biotech sponsors at the center of smarter, faster, and more flexible trials. It's a touchstone for the modular solutions and AI-powered tools that will define the next era of clinical success."
Key updates to the website include:
Focused Study Solutions: Critical standalone service offerings deliver the same high-performance features found in Biorasi's full-service strategies:
Study Rescue and Recovery Packages: Designed to salvage struggling clinical trials and restore timelines.
Flexible Data Sciences Solutions: Advanced analytics and biostatistics available as standalone services.
Specialized Services: Including Quality Assurance, Clinical Monitoring, and Safety & Pharmacovigilance, tailored to sponsor needs.
Accelerated Startup Modules: Fast-track solutions for trials requiring rapid market entry.
AI-Powered Feasibility: Dynamic clinical site modeling combined with targeted feasibility outreach and enrollment forecasting.
New Sponsor Strategy: A sharpened focus on the CRO competencies that matter most: Reliability, Flexibility, and Accessibility.
The redesigned website celebrates Biorasi's over two decades of industry leadership, clinical trial experience, and operational excellence:
Over 200 global studies executed.
Five FDA approvals in the past seven years.
$150M+ in recovered rescue studies.
6 weeks or less for database go-live.
Kickoff Meetings in 10 business days after LOI/WO.
60% repeat business from returning sponsors.
Studies conducted in 48 countries, reaching 65% of the global population.
About Biorasi
Biorasi is a global clinical research organization (CRO) that delivers speed-to-market strategies for small to midsized biotech and biopharma sponsors. With over two decades of expertise in running clinical trials across dermatology, oncology, neurology, nephrology, and other key therapeutic areas, Biorasi leverages reliable, flexible, and accessible solutions necessary to succeed in today's dynamic and evolving clinical trials industry. Contact Biorasi at [email protected] / (786) 388-0700.
SOURCE: Biorasi, LLC
View the original press release on ACCESS Newswire
A.O.Scott--AT